Phase 1 Trial of Alrizomadlin Shows Promise in Targeting Metastatic Salivary Gland Cancers

What happens when one of the rarest cancers has almost no treatment options left? University of Michigan researchers are testing a new targeted drug that is showing encouraging results against aggressive salivary gland cancers, offering fresh hope for patients facing a disease where therapies have remained largely unchanged for years.